Comment on “Major adverse cardiac and cerebrovascular events (MACCEs) in patients with acute ST-segment elevation myocardial infarction(STEMI) treated with pharmaco-invasive strategy with half-dose recombinant human prourokinase (PHDP): Two-year outcomes ”